ACRX Share Price

Open 1.90 Change Price %
High 1.95 1 Day 0.05 2.70
Low 1.85 1 Week 0.00 0.00
Close 1.90 1 Month -0.22 -10.38
Volume 534735 1 Year -1.35 -41.54
52 Week High 5.75
52 Week Low 1.55
ACRX Important Levels
Resistance 2 1.99
Resistance 1 1.95
Pivot 1.90
Support 1 1.85
Support 2 1.81
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)

ACRX Technical Analysis 5
As on 31st Oct 2017 ACRX Share Price closed @ 1.90 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.89 & Strong Sell for SHORT-TERM with Stoploss of 3.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACRX Target for November
1st Target up-side 4.19
2nd Target up-side 5.79
3rd Target up-side 7.4
1st Target down-side -0.39
2nd Target down-side -1.99
3rd Target down-side -3.6
ACRX Other Details
Segment EQ
Market Capital 65612500.00
Sector Healthcare
Industry Medical Appliances & Equipment
Offical website http://www.acelrx.com
ACRX Address
ACRX
351 Galveston Drive
Redwood City, CA 94063
United States
Phone: 650-216-3500
Fax: 650-216-6500
ACRX Latest News
Interactive Technical Analysis Chart AcelRx Pharmaceuticals, Inc. ( ACRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AcelRx Pharmaceuticals, Inc.
ACRX Business Profile
AcelRx Pharmaceuticals, Inc., incorporated on July 13, 2005, is a development-stage company. It is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The Company has completed Phase 2 clinical development for two additional product candidates, the Sufentanil NanoTab BTP Management System, or ARX-02, for the treatment of cancer breakthrough pain (BTP), and the Sufentanil/Triazolam NanoTab, or ARX-03, designed to provide mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. The Company is preparing to initiate two Phase 3 clinical trials for its product candidate, the Sufentanil NanoTab PCA System, or ARX-01. Its operations are based in Redwood City, California.